Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 13/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9246331 | 0.78 | NISCH (0.54) | NISCHKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9868117 | 0.77 | NISCH (0.55) | NISCHKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL29374375 | 0.76 | PSMB5 (0.65) | KDM4EALDH1A1CYP3A4CYP2D6LMNA | |
| SCHEMBL3359420 | 0.76 | PSMB5 (0.65) | KDM4EALDH1A1CYP3A4CYP2D6LMNA | |
| SCHEMBL9065016 | 0.75 | TSHR (0.52) | NISCHKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL31054483 | 0.74 | PSMB5 (0.63) | KDM4EALDH1A1CYP3A4CYP2D6LMNA | |
| Ammonia Solution, Strong SCHEMBL28129677 | 0.74 | PSMB5 (0.63) | KDM4EALDH1A1CYP3A4CYP2D6LMNA | |
| SCHEMBL28846224 | 0.72 | PSMB5 (0.56) | KDM4EALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3399983 | 0.72 | NISCH (0.66) | NISCHKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL105024 | 0.72 | NISCH (1.00) | NISCHALDH1A1CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | claimed |
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | TAKEUCHI KUMIKO (US) | 2004-01-15 | — | — | US | disclosed |
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| WO-1999032482-A1 | HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0924209-A1 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | GPR119, IAPP, GLP1R | NISCH 277/4885KDM4E 2605/4885ALDH1A1 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.